Related Experiment Video
Updated: Jun 18, 2026
05:25
Surgical Porcine Model of Chronic Myocardial Ischemia Treated by Exosome-laden Collagen Patch and Off-pump Coronary Artery Bypass Graft
Published on: September 15, 2023
Coenzyme Q10; an adjunctive therapy for congestive heart failure?
Sarah L Molyneux1, Christopher M Florkowski, A Mark Richards
1Biochemistry Unit, Canterbury Health Laboratories, Christchurch, New Zealand. sarah.molyneux@cdhb.govt.nz
The New Zealand Medical Journal
|December 8, 2009
Summary
Coenzyme Q10 (CoQ10) is vital for cellular energy. Low CoQ10 levels predict survival in chronic heart failure (CHF) patients, suggesting its therapeutic potential.
Area of Science:
- Cardiology
- Biochemistry
- Metabolic Medicine
Background:
- Coenzyme Q10 (CoQ10) is crucial for mitochondrial electron transport and ATP production.
- Myocardial CoQ10 depletion is observed in chronic heart failure (CHF) and correlates with disease severity.
- Plasma CoQ10 levels are an independent predictor of survival in CHF patients.
Purpose of the Study:
- To review the role of Coenzyme Q10 in chronic heart failure.
- To evaluate the impact of CoQ10 supplementation on cardiac function and outcomes in CHF.
- To explore CoQ10's potential as an adjunctive therapy for CHF.
Main Methods:
- Analysis of existing studies, including randomized controlled trials and meta-analyses on CoQ10 in CHF.
- Review of data correlating plasma CoQ10 levels with survival and disease severity.
- Consideration of ongoing clinical trials, such as Q-SYMBIO.
Main Results:
- CoQ10 supplementation has shown positive outcomes in several intervention studies for CHF.
- A meta-analysis indicated CoQ10 improved ejection fraction by 3.7% and cardiac output by 0.28 L/minute.
- Subgroup analysis revealed a 6.7% ejection fraction increase in patients not taking ACE inhibitors.
Conclusions:
- Coenzyme Q10 plays a significant role in cellular energy production and cardiac function.
- Evidence supports CoQ10 as a potential adjunctive therapy for chronic heart failure.
- Further research, including the Q-SYMBIO trial, is needed to confirm survival benefits.
Related Concept Videos
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:30Heart Failure VII: Nursing Interventions
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
01:29Cardiomyopathy VI: Nursing Management
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...